News & Updates

Our Purpose:
To be a driving force in the early detection of lung cancer.

January 2, 2024

Successful validation of LungLB® in multi-site, prospective clinical study

LungLife AI, Inc.(the “Company” or “LungLife”) Successful validation of LungLB® in multi-site, prospective clinical study LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces the successful validation of its LungLB® test for indeterminate lung nodules from a prospective, multi-site clinical study in the clinically important small […]
• Read More
September 28, 2023

Clinical validation study update

LungLife AI, Inc.(the “Company” or “LungLife”) LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, provides an update on the Company’s clinical validation study for its LungLB® test. As stated in the Company’s half-year report on 8 August 2023, LungLife is currently focussed on preparing data from […]
• Read More
August 14, 2023

Director share purchases

LungLife AI, Inc. (the “Company” or “LungLife”)  Director share purchases LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces that it has received notification of the following transactions in the Company’s common shares of US $0.0001 each (“Common Shares”) undertaken by directors. On 14 August 2023, […]
• Read More
August 8, 2023

Half-year Report

LungLife AI, Inc. (the “Company” or “LungLife”)  Half-year Report  LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer announces its unaudited half-year report for the six months ended 30 June 2023. Operational Highlights: Completed enrolment of the Company’s 425-participant pivotal clinical validation study in May, in line […]
• Read More
August 3, 2023

Notice of Results

3 August 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Notice of Results Investor Presentation LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, will announce its unaudited half-year report for the six months ended 30 June 2023 on Tuesday 8 August 2023. Investor presentation Paul Pagano, […]
• Read More
June 6, 2023

LungLB® study demonstrating high performance published in peer-reviewed journal

6 June 2023 LungLife AI, Inc. (the “Company” or “LungLife”) LungLB® study demonstrating high performance published in peer-reviewed journal LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the publication of successful performance results for the Company’s blood-based LungLB® test from a multi-site prospective study in patients with indeterminate pulmonary […]
• Read More
May 23, 2023

Enrolment completed for pivotal validation study of LungLB®

23 May 2023 LungLife AI, Inc. (the “Company” or “LungLife”)  Enrolment completed for pivotal validation study of LungLB® Company to work with clinical sites to ensure data quality ahead of analysis and readout  LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the completion of enrolment for its prospective, pivotal […]
• Read More
May 15, 2023

Block Listing Six Monthly Return

15 May 2023 LungLife AI, Inc. ("LungLife" or the "Company") Block Listing Six Monthly Return LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies: Name of applicant: […]
• Read More
May 4, 2023

Result of Annual General Meeting

4 May 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Result of Annual General Meeting LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at its Annual General Meeting, held at earlier today, all 10 resolutions put to members were passed on a poll. The number of votes lodged […]
• Read More
May 2, 2023

Confirmation of AGM

2 May 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Confirmation of AGM LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, confirms that its Annual General Meeting ("AGM") will be held at 3:00 P.M. (BST) on Thursday 4 May 2023, at Investec Bank plc, 30 Gresham Street, London, EC2V 7QP. […]
• Read More
1 2 3 5

Investor inquiries

LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
crosschevron-down